Summary: In adults with persistent and recalcitrant diabetic foot ulcers that failed to heal with conventional treatment, full-thickness decellularized placental membrane allograft (FT-DPM) applied to the debrided wound bed for 5-9 days with reapplication as needed demonstrated significantly increased complete wound closure rates and accelerated healing time compared to standard of care alone including wound debridement and moist wound therapy without allograft, with primary adverse events limited to mild to moderate wound site irritation that did not prevent continued treatment.
| PICO | Description |
|---|---|
| Population | Adults with persistent and recalcitrant diabetic foot ulcers that failed to heal with conventional treatment. |
| Intervention | Full-thickness decellularized placental membrane allograft (FT-DPM) applied to the debrided wound bed and left in place for 5-9 days, with reapplication as needed. |
| Comparison | Standard of care alone, including wound debridement and moist wound therapy without allograft. |
| Outcome | FT-DPM significantly increased complete wound closure rates and accelerated healing time compared to standard care. Primary adverse events were mild to moderate wound site irritation that did not prevent continued treatment. |
FT-DPM vs standard care for diabetic foot ulcers
RCT · recalcitrant DFU · 12 weeks
FT-DPM nearly doubled 12-week wound closure versus standard care in hard-to-heal diabetic foot ulcers, with greater area reduction and a comparable safety profile.
Clinical Context
Diabetic foot ulcers (DFUs) affect 15-25% of patients during their lifetime. DFUs precede approximately 85% of diabetes-related amputations, and 5-year mortality following major amputation exceeds 50%. Finding effective treatments for recalcitrant wounds is critical.
Placental membranes contain an array of growth factors, cytokines, and extracellular matrix components that promote tissue repair. Decellularization removes immunogenic cells while preserving the bioactive scaffold, creating an “off-the-shelf” product that doesn’t require tissue matching.
Clinical Pearls
1. Full-Thickness Advantage: This product combines amnion and chorion layers, potentially providing more growth factors and matrix components than amnion-only products.
2. Extended Application Interval: The 5-9 day application period reduces office visits and may allow better integration with the wound bed compared to products requiring more frequent changes.
3. Recalcitrant Wound Population: Studying wounds that already failed standard care strengthens the evidence for genuine therapeutic benefit rather than natural healing.
4. Local Irritation Manageable: Mild wound site irritation typically doesn’t preclude continued treatment and resolves with continued care.
Practical Application
Consider placental membrane allografts for diabetic foot ulcers that fail to demonstrate healing progress (less than 50% area reduction) after 4-6 weeks of optimal standard care. Prerequisites include adequate vascular supply (ABI >0.7 or toe pressure >40 mmHg), absence of deep infection, appropriate offloading, and optimized glycemic control.
Document the recalcitrant nature of the wound and failure of standard care to support medical necessity for insurance coverage.
Broader Evidence Context
Multiple placental membrane products are marketed for wound healing, including EpiFix, Grafix, and others. A 2023 Cochrane review found low-certainty evidence that skin substitutes including placental membranes may improve DFU healing compared to standard care. Head-to-head comparisons between products are limited.
Study Limitations
Open-label design may influence outcome assessment by investigators. Industry sponsorship requires consideration of potential bias. Long-term durability of healing and recurrence rates were not reported.
Bottom Line
Full-thickness decellularized placental membrane allograft significantly improves healing rates in recalcitrant diabetic foot ulcers compared to standard care alone, with an acceptable safety profile. Consider for wounds failing conventional therapy.
Source: Reyzelman AM, et al. “Efficacy of a Full-Thickness Decellularised Placental Membrane Allograft Compared to Standard of Care in Diabetic Foot Ulcers: A Prospective, Randomised Controlled Trial.” Read article.